摘要
目的:观察并对比瑞格列奈联合阿卡波糖与瑞格列奈联合二甲双胍治在2型糖尿病患者治疗中的临床效果。方法:选择我院在2017年11月至2019年4月之间收治的62例2型糖尿病患者,随机分为两组。甲组予以瑞格列奈联合二甲双胍治疗,乙组予以瑞格列奈联合阿卡波糖治疗。观察并分析两组患者的临床治疗效果。结果:乙组患者高密度脂蛋白胆固醇(HDL-C)水平较甲组明显更高,且低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)水平更低,P<0.05;乙组患者胰高血糖素样肽-1(GLP-1)、空腹胰岛素(FIns)水平较甲组明显更高,胰岛素抵抗指数(,HOMA-IR)、HbAlc、餐后2h血糖(2hPBG)以及空腹血糖(FBG)水平更低,P<0.05;乙组患者不良反应发生率较甲组明显更低,P<0.05;乙组患者治疗总有效率较甲组明显更高,P<0.05。结论:2型糖尿病患者治疗中采用瑞格列奈联合二甲双胍和阿卡波糖均具有一定疗效,但是后者安全性更高,患者血糖、胰岛素以及脂代谢改善更加明显,值得进一步研究。
Objection:To observe and compare the clinical effect of repaglinide combined with acarbose and repaglinide combined with metformin in the treatment of type 2 diabetes patients.Methods:To observe and compare the clinical effect of repaglinide combined with acarbose and repaglinide combined with metformin in the treatment of type 2 diabetes patients.Results:HDL-C level in group b was significantly higher than that in group a,and LDL-C,TG and TC levels were lower,P<0.05.The levels of GLP-1 and FIns in group b were significantly higher than those in group a,and the levels of HOMA-IR,HbAlc,2hPBG and FBG were lower,P<0.05.The incidence of adverse reactions in group b was significantly lower than that in group a(P<0.05).The total effective rate of group b was significantly higher than that of group a,P<0.05.Conclusion:Repaglinide combined with metformin and acarbose in the treatment of patients with type 2 diabetes has certain efficacy,but the latter is safer,and the improvement of blood glucose,insulin and lipid metabolism in patients is more obvious,which deserves further study.
作者
陈文娜
CHEN Wen-na(Yingtan People’s Hospital,Yingtan Jiangxi 335000,China)
出处
《药品评价》
CAS
2019年第21期62-63,共2页
Drug Evaluation
